The US Food and Drug Administration (FDA) has approved fitusiran (Qfitlia, Sanofi) for bleeding prophylaxis in patients aged 12 years or older with hemophilia A and B with or without factor VIII ...

The drug fitusiran, which will go by the brand name Qfitlia, is the first new treatment for both types of hemophilia — A and B. It can also be given to both patients who have antibodies that ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages ...